CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration

Chimeric antigen receptor–engineered T cells targeting CD19 (CART19) provide an effective treatment for pediatric acute lymphoblastic leukemia but are less effective for chronic lymphocytic leukemia (CLL), focusing attention on improving efficacy. CART19 harbor an engineered receptor, which is deliv...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:J Clin Invest
Main Authors: Nobles, Christopher L., Sherrill-Mix, Scott, Everett, John K., Reddy, Shantan, Fraietta, Joseph A., Porter, David L., Frey, Noelle, Gill, Saar I., Grupp, Stephan A., Maude, Shannon L., Siegel, Donald L., Levine, Bruce L., June, Carl H., Lacey, Simon F., Melenhorst, J. Joseph, Bushman, Frederic D.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society for Clinical Investigation 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994131/
https://ncbi.nlm.nih.gov/pubmed/31845905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI130144
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים